It has been demonstrated that one of Vitamin D Binding Protein (DBP)
biological functions is to enhance the chemotactic activity of C5a and
C5a des Arg. The present invention has found that peptides having
sequences that substantially correspond to a specific region in the
N-terminal domain I of DBP can block the DBP enhancement of C5a or C5a
des Arg chemotactic activity. Based in this discovery the present
invention provides DBP antagonist peptides and the use thereof for the
treatment C5a or C5a des Arg-mediated disorders.